Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non–small-cell lung cancer
- 1 January 2002
- journal article
- Published by Elsevier in Human Pathology
- Vol. 33 (1), 105-110
- https://doi.org/10.1053/hupa.2002.30183
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Do Molecular Markers Predict Survival in Non–Small-Cell Lung Cancer?American Journal of Respiratory and Critical Care Medicine, 1998
- Time trends and survival after operations for primary lung cancer from 1976 through 1990The Journal of Thoracic and Cardiovascular Surgery, 1996
- Correlation of Intratumoral Microvessel Density and p53 Protein Overexpression in Human Colorectal AdenocarcinomaMicrovascular Research, 1996
- Survival in early-stage non-small cell lung cancerThe Annals of Thoracic Surgery, 1995
- Loss of Heterozygosity at the bcl‐2 Gene Locus and Expression of bcl‐2 in Human Gastric and Colorectal CarcinomasJapanese Journal of Cancer Research, 1994
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- bcl-2 Protein in Non-Small-Cell Lung CarcinomaNew England Journal of Medicine, 1993
- Bcl‐2 proto‐oncogene expression in epstein‐barr‐virus‐associated nasopharyngeal carcinomaInternational Journal of Cancer, 1993
- Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell deathNature, 1990
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987